Toggle Main Menu Toggle Search

ePrints

A comparison of the efficacy of donepezil in parkinson's disease with dementia and dementia with lewy bodies

Lookup NU author(s): Professor Alan Thomas, Professor David Burn, Dr Elise Rowan, Elizabeth Littlewood, Dr Jane Newby, Dr David Cousins, Dr Sanjeet Pakrasi, Dr Jonathan Richardson, Dr Jonathan Sanders, Professor Ian McKeith

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Background: Parkinson's disease with dementia (PDD) and dementia with Lewy bodies (DLB) overlap in phenomenology and neurochemical deficits. We hypothesised they would not differ in their response to the cholinesterase inhibitor donepezil. Methods: We recruited 70 subjects, 30 DLB and 40 PDD, in an open label study to compare the efficacy of donepezil in these two patient groups. They were assessed at baseline, 4, 12 and 20 weeks. The main outcome measures were the Mini-Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI) and motor sub-section of the Unified Parkinson's Disease Rating Scale (UPDRS III). Results: PDD patients were younger than DLB and had more severe parkinsonism at baseline. The groups were similar on all other variables of interest. By 20 weeks the mean MMSE score increased by 3.9 points in the DLB group and by 3.2 points in PDD. The mean NPI score reduced by 14.6 points for DLB and 12.0 points for PDD. These treatment effects were all significant compared to baseline (p < 0.001) but there were no significant between-group treatment differences (MMSE p = 0.56, NPI p = 0.39). UPDRS III motor scores did not change significantly from baseline values in either group. Although adverse effects were common (69%) they were usually mild and 64 patients (91%) completed the study. The four patients who did withdraw with adverse effects all had a PDD diagnosis. Conclusions: Donepezil produced similar improvements in cognition and behaviour in DLB and PDD. This supports the hypothesis that the two disorders are closely related clinically and neurobiologically. Larger scale, placebo controlled clinical trials are needed to provide an evidence base to guide the clinical use of cholinesterase inhibitors in Lewy body disease. Copyright © 2005 John Wiley & Sons, Ltd.


Publication metadata

Author(s): Thomas AJ, Burn DJ, Rowan EN, Littlewood E, Newby J, Cousins D, Pakrasi S, Richardson J, Sanders J, McKeith IG

Publication type: Article

Publication status: Published

Journal: International Journal of Geriatric Psychiatry

Year: 2005

Volume: 20

Issue: 10

Pages: 938-944

ISSN (print): 0885-6230

ISSN (electronic): 1099-1166

Publisher: Wiley-Blackwell

URL: http://dx.doi.org/10.1002/gps.1381

DOI: 10.1002/gps.1381

PubMed id: 16163744


Altmetrics

Altmetrics provided by Altmetric


Actions

    Link to this publication


Share